Spots Global Cancer Trial Database for A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Official Title: Masked, Randomized, Single-site, Crossover Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 Dosed for 14 Days in Adult Subjects With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Study ID: NCT04947124

Conditions

Sturge-Weber Syndrome (SWS)

Glaucoma

Glaucoma Congenital

Ocular Hypertension

Interventions

QLS-101ophthalmic solution 1%

QLS-101ophthalmic solution 2%

Study Description

Brief Summary: Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).

Detailed Description: Masked, randomized, single site, crossover study to compare 2 concentrations of QLS-101. Subjects will be randomized to one of 2 concentrations of QLS-101 for the first 14 days of daily dosing, and after a 14-day washout period they will be crossed over to the other concentration for another 14 days of daily dosing. Dose assignment is masked to patient and investigator.